Syndax Pharmaceuticals, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:SNDX) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 724.82 M640.71 M596.15 M551.79 M529.71 M472.67 M Total liabilities 436.69 M425.65 M438.73 M436.36 M465.08 M431.05 M Total equity 288.12 M215.06 M157.42 M115.43 M64.63 M41.62 M Total liabilities & shareholders' equities 724.82 M640.71 M596.15 M551.79 M529.71 M472.67 M Total debt 675.25 M————— Net debt 102.36 M—————

News

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth

Kura Oncology: Commercialization In AML Presents Asymmetric Upside (NASDAQ:KURA)

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Syndax Pharmaceuticals at Barclays Conference: Strategic Growth Focus

Syndax at Leerink Conference: Strategic Growth and Profitability

Syndax Pharmaceuticals stock hits 52-week high at $22.91

Syndax at TD Cowen Conference: Strategic Growth and Financial Strength

Stifel raises Syndax Pharmaceuticals stock price target on drug sales

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript

Syndax Q4 2025 slides: revenue surges 50%, profitability path outlined

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates